MARKET WIREYahoo Finance • 21h ago
X4 Pharmaceuticals Enters Up to $150 Million Term Loan FacilityYahoo Finance report covering X4 Pharmaceuticals Inc. (XFOR) market action, institutional positioning, and fundamental catalysts.
Why XFOR Stock Traded Steady Today — RQD Quant Desk Flash
$3.35 0.00% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $3.34
X4 Pharmaceuticals Inc. (XFOR) carries a Roarable Rating of E (Strong Sell) with 29/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $332.1M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on XFOR Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is XFOR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, X4 Pharmaceuticals Inc. (NASDAQ: XFOR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $3.35 (0.00% 1D, market cap $332.1M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, XFOR ranks #830 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does XFOR compare to ALEC and KYTX in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), XFOR carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of 83.6%, and ROIC of -35.0%. By comparison, ALEC (Alector Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $327.6M) and KYTX (Kyverna Therapeutics Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $350.7M). Among the 5-stock peer group, XFOR leads on earnings multiple (N/A) while XFOR leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for XFOR?
▼
Per XFOR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001501697), X4 Pharmaceuticals Inc. generated $35.1M in revenue (+1273.2% YoY), -$79.2M in net income, and -$85.6M in free cash flow against $290.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $3.34 (-0.19%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (29/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.8% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk E
Each axis scored 0–20
12M PRICE TARGET CONE-13.1% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for XFOR)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (29/100 Composite)
🔍 WHY XFOR SCORES 29/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+9/20 pts (31% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▲ #2 Bullish Driver: Macro Regime Fit+7/20 pts (24% of score)
FRED Regime × Technicals: 38% of 52W Range • RSI-14 at 60.1 (BULLISH MOMENTUM)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$2.60+16.2% Next Q
21
Q2 (-2Q)Grade E$3.02+7.6% Next Q
24
Q3 (-1Q)Grade E$3.25+3.1% Next Q
26
CurrentGrade E$3.35-9.8% Hist 90D α
29
Trajectory: E (21) → E (29)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a XFOR Turnaround Squeeze
While XFOR currently carries a cautious 29/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.30) and Max Pain ($3.52) forces dealer call-delta covering toward $5.07.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $XFOR• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “XFOR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why XFOR Stock Traded Steady Today — RQD Quant Desk Flash
X4 Pharmaceuticals Inc. (XFOR) slipped 0.00% to $3.35, trading at 38% of its 52-week range ($2.43 – $4.83). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 38% of its 52-week range ($2.43 – $4.83) with RSI-14 at 60.1 (BULLISH MOMENTUM).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $3.35 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 83.6% gross margin and $0 annual free cash flow.
Live XFOR Headlines & Catalysts
MARKET WIREMoomoo • 1d ago
X4 Pharmaceuticals(XFOR) Stock Options Chain | Quotes & NewsMoomoo report covering X4 Pharmaceuticals Inc. (XFOR) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingView • 1d ago
X4 Pharmaceuticals, Inc. Estimates – NASDAQ:XFORTradingView report covering X4 Pharmaceuticals Inc. (XFOR) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 1d ago
X4 Pharmaceuticals Secures Up to $150 Million in New Debt Financing From K2 HealthVenturesYahoo Finance report covering X4 Pharmaceuticals Inc. (XFOR) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
A second mavorixafor study is planned for Q1 2027 at X4 Pharmaceuticals (XFOR).Stock Titan report covering X4 Pharmaceuticals Inc. (XFOR) market action, institutional positioning, and fundamental catalysts.
MARKET WIREad-hoc-news.de • 1d ago
X4 Pharmaceuticals stock: Wells Fargo keeps Buy rating for X4 Pharmaceuticals stock at USD 11.00ad-hoc-news.de report covering X4 Pharmaceuticals Inc. (XFOR) market action, institutional positioning, and fundamental catalysts.
MARKET WIREad-hoc-news.de • 1d ago
X4 Pharmaceuticals stock: Chairman Adam Craig buys 4,600 shares of X4 Pharmaceuticals stockad-hoc-news.de report covering X4 Pharmaceuticals Inc. (XFOR) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETipRanks • 1d ago
X4 Pharmaceuticals Highlights Strategic Focus on Rare HematologyTipRanks report covering X4 Pharmaceuticals Inc. (XFOR) market action, institutional positioning, and fundamental catalysts.
RISK WATCHSeekingAlpha • 4d ago
X4 Pharmaceuticals, Inc. (XFOR) Analyst/Investor Day TranscriptX4 Pharmaceuticals, Inc. (XFOR) Analyst/Investor Day October 29, 2026 10:00 AM EDTCompany ParticipantsAdam Craig - Executive ChairJohn Volpone - President...
MARKET WIREYahoo • 4d ago
X4 Pharmaceuticals Highlights Clinical Progress and Market Opportunity for Mavorixafor in Primary Chronic Neutropenia During Virtual Investor Day- Base Case U.S. Market Opportunity Estimated at 15,000 Patients, With Potential to Expand to Approximately 30,000 Patients - - On Track for Completion of 4WARD Phase 3 Target Enrollment in Q4 2026 - - Planned 4STEPS Pha
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring XFOR)
- ✓Walkthrough of XFOR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
XFOR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -20.43%📐 HORIZONTAL RANGE
2026-11-03O $3.36H $3.36L $3.35C $3.35VOL 706.3K
RES: $5.04SUP: $2.16SMA50: $3.30SMA200: $3.80
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
XFOR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth
vs. +1273.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on XFOR today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for XFOR. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for XFOR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (XFOR)
Health Care Rank #830 of 1015
⚔️ ALEC vs XFOR Full Matrix →
1. Head-to-Head Health Care Peer Comparison (XFOR vs. ALEC, KYTX, AGEN, IRLA)
Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, X4 Pharmaceuticals Inc. (XFOR) ranks #830 by composite RQD confidence (29/100, grade E) and #504 by equity capitalization ($332.1M). Within this direct 5-issuer industry benchmark cohort, XFOR leads on earnings valuation at N/A trailing P/E, while XFOR leads on capital efficiency and profitability with -35.0% ROIC and 83.6% gross margin. KYTX currently holds the highest overall quantitative score in the immediate peer group at 35/100 (D-) compared with XFOR at 29/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| XFOR
ACTIVE
X4 Pharmaceuticals Inc. | E | 29/100 | — | 83.6% | -35.0% | 0.00% | $332.1M | Benchmark Subject |
| ALEC Alector Inc. | E | 33/100 | — | — | -35.0% | -2.71% | $327.6M | /alec-vs-xfor → |
| KYTX Kyverna Therapeutics Inc. | D- | 35/100 | — | — | -35.0% | -7.94% | $350.7M | /kytx-vs-xfor → |
| AGEN Agenus Inc. | E | 29/100 | — | 96.0% | -35.0% | -4.53% | $308.9M | /agen-vs-xfor → |
| IRLA IRulya Therapeutics Inc. | E | 34/100 | — | — | -35.0% | +1.82% | $357.2M | /irla-vs-xfor → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001501697 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), X4 Pharmaceuticals Inc. (XFOR) reported GAAP revenue of $35.1M (+1273.2% vs. FY2024 revenue of $2.6M , and -88.3% cumulative change since FY2023) , GAAP net income of -$79.2M, operating cash flow of -$85.6M, and free cash flow of -$85.6M (+34.8% YoY). On the balance sheet, XFOR closed FY2025 with $290.5M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $35.1M | -$79.2M | -$85.6M | -$85.6M | $290.5M | — |
| FY2024 (FY) | 2024-12-31 | $2.6M | -$37.5M | -$130.9M | -$131.2M | $146.4M | — |
| FY2023 (FY) | 2023-12-31 | $301.1M | -$101.2M | -$96.5M | -$96.5M | — | — |
3. XFOR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs XFOR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, X4 Pharmaceuticals Inc. (NASDAQ: XFOR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $3.35 (0.00% 1D, market cap $332.1M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, XFOR ranks #830 in composite RQD confidence.
How does XFOR compare to ALEC and KYTX in the Health Care sector?
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), XFOR carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of 83.6%, and ROIC of -35.0%. By comparison, ALEC (Alector Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $327.6M) and KYTX (Kyverna Therapeutics Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $350.7M). Among the 5-stock peer group, XFOR leads on earnings multiple (N/A) while XFOR leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for XFOR?
Per XFOR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001501697), X4 Pharmaceuticals Inc. generated $35.1M in revenue (+1273.2% YoY), -$79.2M in net income, and -$85.6M in free cash flow against $290.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Where is XFOR trading relative to its 50-day, 200-day, and 52-week technical levels?
XFOR last traded at $3.35 (0.00% on volume of 521,970 shares), positioning the stock +1.52% above its 50-day simple moving average ($3.30) and -11.84% below its 200-day simple moving average ($3.80). Across its 52-week range of $2.43 to $4.83, XFOR sits at the 38.3% percentile with a 14-day RSI of 60.1 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($2.93 to $3.77).
ROARABLE RATING BRIEF • RQD 29/100 (E)
✓ SEC XBRL & RQD VERIFIED
XFOR — X4 Pharmaceuticals Inc.: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
X4 Pharmaceuticals Inc. (XFOR) earns a live Roarable RQD composite score of 29/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $3.35 (0.00% 1D, market capitalization $332.1M).
- Fundamental Cash Engine (5/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 83.6%, operating margin of -60.0%, and free cash flow yield of —.
- Whale 13F & Options Flow (9/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (7/20) + Forensic Balance Sheet (5/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.20, Piotroski F-Score of 3/9, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
X4 Pharmaceuticals Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Biological Products (No Diagnostic Substances) industry. The company's product sales, customer base, and revenue model are not described in the supplied source data. The SEC financials show reported revenue of $35.1M in FY 2025, up from $2.6M in FY 2024 and — in FY 2023. Per the market data, gross margin is 83.6%.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), X4 Pharmaceuticals Inc. (XFOR) reported $35.1M in annual revenue (up from $2.6M in FY2024, +1273.2% YoY) and -$79.2M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($301.1M revenue, -$101.2M net income) through FY2025, XFOR scaled operating cash flow to -$85.6M and free cash flow to -$85.6M, backed by $290.5M in total assets against $0 in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (E • RQD 29/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 9/20. With Fundamental Cash Engine at 5/20 and Institutional Whale Flow at 9/20, sustained execution supports upside toward the upper end of the $2.43 – $4.83 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
Upstream and downstream dependencies, therefore, cannot be mapped from the supplied data. Sector correlation is limited to the profile classification (Health Care; Biotechnology: Biological Products) and the Roarable RQD macro regime pillar, which records beta of 1.0 and a sector sensitivity score within 7 of 20. A prospective investor should watch whether the financing and the planned Q1 2027 study alter the cash trajectory, since the supplied data contains no second-order supplier or customer linkages to test that effect.
- Key Question #1: Can XFOR sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $35.1M and free cash flow of -$85.6M, how will capital allocation balance growth reinvestment against $0 in total debt?
- Key Question #3: How sensitive is XFOR's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
XFOR Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for X4 Pharmaceuticals Inc. (XFOR) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo Finance • 21h ago
X4 Pharmaceuticals Enters Up to $150 Million Term Loan Facility Yahoo Finance report covering X4 Pharmaceuticals Inc. (XFOR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Moomoo • 1d ago
X4 Pharmaceuticals(XFOR) Stock Options Chain | Quotes & News Moomoo report covering X4 Pharmaceuticals Inc. (XFOR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 1d ago
X4 Pharmaceuticals, Inc. Estimates – NASDAQ:XFOR TradingView report covering X4 Pharmaceuticals Inc. (XFOR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
X4 Pharmaceuticals Secures Up to $150 Million in New Debt Financing From K2 HealthVentures Yahoo Finance report covering X4 Pharmaceuticals Inc. (XFOR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
A second mavorixafor study is planned for Q1 2027 at X4 Pharmaceuticals (XFOR). Stock Titan report covering X4 Pharmaceuticals Inc. (XFOR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE ad-hoc-news.de • 1d ago
X4 Pharmaceuticals stock: Wells Fargo keeps Buy rating for X4 Pharmaceuticals stock at USD 11.00 ad-hoc-news.de report covering X4 Pharmaceuticals Inc. (XFOR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE ad-hoc-news.de • 1d ago
X4 Pharmaceuticals stock: Chairman Adam Craig buys 4,600 shares of X4 Pharmaceuticals stock ad-hoc-news.de report covering X4 Pharmaceuticals Inc. (XFOR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TipRanks • 1d ago
X4 Pharmaceuticals Highlights Strategic Focus on Rare Hematology TipRanks report covering X4 Pharmaceuticals Inc. (XFOR) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
XFOR Bull vs. Bear Conversation Board — What's Your Call at $3.35?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON XFOR 🐻 33% BEARISH CONVICTION
DE DeltaGamma_99 RQD DEBATE OPENER • Options Flow Specialist 🐂 BULLISH
🎯 Target: $4.29 (+28.1%)
📌 Pinned Debate FY 2025 revenue reached $35.1M, up from $2.6M in FY 2024, and reported cash rose to $217.0M.
Picked up a starter position in XFOR in my $100K Virtual Cash book at $3.35. FY 2025 revenue reached $35.1M, up from $2.6M in FY 2024, and reported cash rose to $217.0M.. Trading inside a $2.43–$4.83 52-week range with 0.0% FCF yield gives solid downside support if Biotechnology: Biological Products (No Diagnostic Substances) multiples expand this quarter.
EarningsSniper 🐂 BULL
Both sides have a point here — XFOR's 5/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.
FO ForensicBear RQD DEBATE OPENER • 10-K Footnote Auditor 🐻 BEARISH
🎯 Target: $2.58 (-23.0%)
Spot @ $3.35 Operating margin of -60% and ROIC of -35% sit alongside an Altman Z-Score of 0.2 and a Piotroski F-Score of 3/9.
Careful chasing XFOR at $3.35. Operating margin of -60% and ROIC of -35% sit alongside an Altman Z-Score of 0.2 and a Piotroski F-Score of 3/9.. Gross margin is 83.6%, but operating margin is -60.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $2.58 on multiple compression.